CADTH | Evidence Driven
CADTH | Evidence Driven

Nivolumab and Ipilimumab

Details

Files
Generic Name:
Nivolumab and Ipilimumab
Project Status:
Active
Therapeutic Area:
Melanoma (Skin)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
PX0347-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open09-Nov-23
Call for patient/clinician input closed08-Jan-24
Call for industry input open09-Nov-23
Call for industry input closed08-Jan-24
Submission received24-Oct-23

Files

Proposed Project Scope View PDF

Related Content

Last Updated : December 18, 2023